A Probe for NIR-II Imaging and Multimodal Analysis of Early Alzheimer’s Disease by Targeting CTGF

Cao Lu,Cong Meng,Yuying Li,Jinling Yuan,Xiaojun Ren,Liang Gao,Dongdong Su,Kai Cao,Mengchao Cui,Qing Yuan,Xueyun Gao
DOI: https://doi.org/10.1038/s41467-024-49409-4
IF: 16.6
2024-01-01
Nature Communications
Abstract:To date, earlier diagnosis of Alzheimer's disease (AD) is still challenging. Recent studies revealed the elevated expression of connective tissue growth factor (CTGF) in AD brain is an upstream regulator of amyloid-beta (A beta) plaque, thus CTGF could be an earlier diagnostic biomarker of AD than A beta plaque. Herein, we develop a peptide-coated gold nanocluster that specifically targets CTGF with high affinity (KD similar to 21.9 nM). The probe can well penetrate the blood-brain-barrier (BBB) of APP/PS1 transgenic mice at early-stage (earlier than 3-month-old) in vivo, allowing non-invasive NIR-II imaging of CTGF when there is no appearance of A beta plaque deposition. Notably, this probe can also be applied to measuring CTGF on postmortem brain sections by multimodal analysis, including fluorescence imaging, peroxidase-like chromogenic imaging, and ICP-MS quantitation, which enables distinguishment between the brains of AD patients and healthy people. This probe possesses great potential for precise diagnosis of earlier AD before A beta plaque formation.
What problem does this paper attempt to address?